Cogent Biosciences (COGT) Earnings
Price: $5.33
Market Cap: $606.82M
Market Cap: $606.82M
Revenue (TTM): $-
Net Income: $-255.86M
Net Income: $-255.86M
P/E Ratio: -2.30
EPS (TTM): $-2.32
EPS (TTM): $-2.32
Earnings Dates
Cogent Biosciences (COGT) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 06, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.55
Last Earnings Report
- Date: February 25, 2025
- EPS: $-0.09
- EPS Estimate: $-0.59
Cogent Biosciences's next earnings report is scheduled for May 06, 2025.
In its last earnings report on February 25, 2025, Cogent Biosciences reported earnings per share (EPS) of $-0.09, compared to an estimated EPS of $-0.59. The company reported revenue of $-, compared to an estimated revenue of $-.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| February 25, 2025 | $-0.09 | $-0.59 | $- | $- |
| November 12, 2024 | $-0.64 | $-0.55 | $- | $- |
| August 06, 2024 | $-0.59 | $-0.55 | $- | $- |
| May 07, 2024 | $-0.62 | $-0.50 | $- | $- |
| February 26, 2024 | $-0.63 | $-0.54 | $5.59M | $- |
| November 02, 2023 | $-0.64 | $-0.50 | $- | $- |
| August 08, 2023 | $-0.59 | $-0.53 | $- | $- |
| May 09, 2023 | $-0.54 | $-0.58 | $- | $- |
| March 14, 2023 | $-0.56 | $-0.50 | $- | $- |
| November 14, 2022 | $-0.50 | $-0.51 | $- | $- |
| August 09, 2022 | $-0.71 | $-0.64 | $- | $- |
| May 10, 2022 | $-0.68 | $-0.53 | $- | $- |
| March 15, 2022 | $-0.61 | $-0.55 | $- | $- |
| November 10, 2021 | $-0.48 | $-0.43 | $- | $- |
| August 16, 2021 | $-0.43 | $-0.39 | $- | $- |
| May 12, 2021 | $-0.34 | $-0.46 | $- | $- |
| March 16, 2021 | $-6.03 | $-0.30 | $0 | $- |
Annual Earnings
Annual Revenue
$-
Fiscal Year 2024Annual Net Income
$-255.86M
Fiscal Year 2024Annual EPS
$-3.49
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-67.93M
Quarter Ending December 31, 2024EPS
$-0.61
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-44.72%
Year Ending December 31, 2024P/E Ratio
-2.24
Year Ending December 31, 2024Revenue Per Share
$0.00
Year Ending December 31, 2024Earnings Yield (TTM)
-43.46%
Trailing Twelve MonthsP/E Ratio (TTM)
-2.30
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.00
Trailing Twelve MonthsFrequently Asked Questions
Cogent Biosciences's next earnings date is scheduled for May 06, 2025. The earnings call is expected to take place before market open.
In its last earnings report on February 25, 2025, Cogent Biosciences reported earnings per share (EPS) of $-0.09, compared to an estimated EPS of $-0.59. The company reported revenue of $-, compared to an estimated revenue of $-.
Cogent Biosciences's current Price-to-Earnings (P/E) ratio is -2.24. The trailing twelve months (TTM) P/E ratio is -2.30. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Cogent Biosciences reported total revenue of $- and net income of $-255.86M. This represents a net profit margin of 0.
Cogent Biosciences's earnings yield is -44.72%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Cogent Biosciences's return on equity (ROE) is -99.83%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Cogent Biosciences's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for COGT.